Biocytogen officially launches the RenMice
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice ® series , which includes a collection of independently developed fully human antibody mice and TCR mice with proprietary intellectual property. The term “Ren”, defined as “human”, comes from the Chinese pinyin for “人” (rén), which incorporates oriental cultural elements and represents Biocytogen’s commitment to developing innovative technologies that advance discovery, development and the provision of new therapies beneficial to human health. The RenMice ® series includes five strains of fully human antibody/mouse TCR mice: RenMab™, RenLite® , RenNano ® , RenTCR™ and RenTCR-mimic™. These mice provide strong support for the discovery of fully human monoclonal antibodies, bispecific antibodies, bispecific antibody drug conjugates (ADCs), nanobodies, fully human T cell receptors (TCRs), and TCR mimic antibodies . Biocytogen is also generating more fully human RenMice strains for MHC cluster genes, NK cell cluster genes and other gene clusters for various drug development purposes, which will be integrated into the RenMice portfolio after a successful development.
Since its launch in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field. As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide, and 42 targeted antibody development projects have been initiated. Additionally, 50 antibody drug co-development/licensing/transfer agreements have been concluded with partners around the world. As Biocytogen’s Project Integrum has completed over 900 target-specific antibody discovery projects and identified between 400,000 and 500,000 antibody molecules, the number of external co-development/licensing/transfer agreements for therapeutic antibodies is expected to increase significantly. The successful development of new RenMice platforms will further strengthen Biocytogen’s technical capabilities in new drug discovery and accelerate the development of new treatments in collaboration with global partners.
